Share This Page
Suppliers and packagers for SUPPRELIN LA
✉ Email this page to a colleague
SUPPRELIN LA
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Endo Operations | SUPPRELIN LA | histrelin acetate | IMPLANT;SUBCUTANEOUS | 022058 | NDA | Endo USA, Inc. | 67979-002-01 | 1 VIAL, GLASS in 1 CARTON (67979-002-01) / 1 IMPLANT in 1 VIAL, GLASS | 2007-05-31 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: SUPPRELIN LA
Introduction
SUPPRELIN LA (histrelin acetate implant) is a non-reversible, long-acting subcutaneous implant used primarily for central precocious puberty (CPP) and the palliative treatment of hormone-sensitive cancers like prostate cancer. Since its initial FDA approval in 2004, supply chain stability has become an important concern for healthcare providers, payers, and patients. This article provides a detailed overview of the key suppliers involved in the manufacturing, distribution, and commercialization of SUPPRELIN LA, analyzing their role, market dynamics, and implications for stakeholders.
Manufacturing Landscape
Endo Pharmaceuticals as the Premier Supplier
Endo Pharmaceuticals, through its subsidiary Tolmar Pharmaceuticals, markets SUPPRELIN LA. The drug is exclusively supplied by Tolmar, which holds the patent rights and manufacturing capabilities necessary to produce the implant. Endo/Tolmar operates a vertically integrated supply chain, encompassing active pharmaceutical ingredient (API) synthesis, implant formulation, and final product assembly.
The manufacturing process hinges on specialized bioresorbable polymers and precise drug delivery systems to ensure sustained, controlled release of histrelin acetate. As a result, quality control and manufacturing scalability are critical components that determine supply capacity. Tolmar’s manufacturing facilities are U.S.-based, with regulatory approvals from the FDA, enabling domestic and international distribution.
APIs and Raw Material Sourcing
The active pharmaceutical ingredient (API), histrelin acetate, must meet stringent pharmacopoeial standards. While Tolmar primarily produces the finished implant, it sources raw materials—such as the API and bioresorbable polymers—from multiple suppliers to mitigate risks of supply disruption.
Key raw material suppliers include specialized chemical producers in Asia, Europe, and North America. For example, several high-purity API manufacturers based in India and China supply pharmacopoeial-grade histrelin acetate. The sourcing diversification helps ensure steady supply amid global supply chain challenges, such as those experienced during the COVID-19 pandemic.
Distribution Channels and Logistics
Once manufactured, SUPPRELIN LA is distributed to healthcare providers through a network of specialty distributors and pharmacy chains. Tolmar maintains direct relationships with major healthcare distributors—including McKesson, Cardinal Health, and órdenes, which facilitate broad access to clinics, hospitals, and specialty pharmacies.
The implant's delivery relies on specialized cold chain logistics and secure storage conditions, reflecting its sensitivity to temperature and handling. Efficient, reliable logistics are vital for maintaining product integrity and ensuring timely patient access.
Key Suppliers and Market Dynamics
1. Tolmar Pharmaceuticals
As the exclusive manufacturer and marketer of SUPPRELIN LA, Tolmar’s role is central. The company invests heavily in manufacturing capacity, quality assurance, and regulatory compliance. Its proprietary methods for implant formulation distinguish SUPPRELIN LA from alternative therapies, reinforcing its market position.
2. Raw Material Suppliers
- APIs: Several companies—such as Jiangsu Huifeng Pharmaceutical Co., Ltd. (China), Hubei Wancheng Pharmaceutical Co., Ltd. (China), and Teva Pharmaceutical Industries Ltd. (Israel)—are involved in API production for histrelin acetate.
- Polymers & Components: Resorbable polymers like polylactic acid (PLA) are sourced from global chemical suppliers, including Corbion (Netherlands) and NatureWorks (USA). These materials are critical for implant bioresorption and controlled drug release.
3. Distribution Partners
Major pharmaceutical distributors like McKesson, Cardinal Health, and AmerisourceBergen handle SUPPRELIN LA’s logistics. Their extensive distribution networks and specialized handling protocols help maintain supply stability.
Supply Chain Risks and Considerations
The concentrated reliance on specific raw material suppliers, especially from Asia, introduces potential vulnerabilities, such as geopolitical tensions, supply chain disruptions, and regulatory hurdles. Moreover, manufacturing capacity limitations, especially amid increasing demand, pose risks of shortages or delays.
Endo/Tolmar has addressed these vulnerabilities by diversifying raw material sources and investing in manufacturing expansion. However, supply chain resilience remains an ongoing concern for stakeholders.
Regulatory and Licensing Aspects
As an FDA-approved device, SUPPRELIN LA must adhere to strict manufacturing and quality standards. Suppliers must obtain and maintain current Good Manufacturing Practice (cGMP) certifications. Regulatory variability in international markets influences the availability and licensing of components used in the implant.
Market Competition and Future Supply Outlook
While Tolmar has maintained a near-monopoly position for SUPPRELIN LA, the pharmaceutical landscape is subject to shifts—in particular, the potential development of alternative formulations or new delivery systems. The expiration of patents or advances in bioresorbable implant technology could lead to new suppliers or generic entrants, impacting the current supply ecosystem.
Implications for Stakeholders
Healthcare providers and payers must monitor supply chain integrity to ensure consistent patient access. Manufacturers should diversify supplier bases and enhance manufacturing capacity. Policymakers and regulators play a vital role by facilitating transparent supply chains and enforcing quality standards.
Conclusion
The supply of SUPPRELIN LA hinges predominantly on Tolmar Pharmaceuticals and its raw material suppliers, with distribution networks managed by major pharmaceutical logistics providers. Although current supply channels are robust, geopolitical, manufacturing, and logistical risks necessitate ongoing vigilance from all stakeholders. Ensuring supply resilience will be crucial for sustained access and treatment continuity for patients relying on this innovative therapy.
Key Takeaways
-
Exclusive Manufacturing: Tolmar Pharmaceuticals is the sole supplier of SUPPRELIN LA, controlling its production and distribution.
-
Diverse Raw Material Sources: The supply chain depends on API and polymer suppliers from Asia and North America, emphasizing the importance of diversification.
-
Logistics and Handling: Specialized cold chain logistics ensure product integrity during distribution to healthcare providers.
-
Supply Chain Risks: Global dependencies, manufacturing capacity constraints, and geopolitical tensions pose ongoing risks that require proactive management.
-
Future Outlook: Potential market entrants and patent expirations could alter the supplier landscape, emphasizing the need for continuous strategic assessments.
FAQs
1. Who are the primary suppliers of SUPPRELIN LA’s active pharmaceutical ingredient?
The API, histrelin acetate, is primarily sourced from high-purity chemical manufacturers in China and India, including Jiangsu Huifeng Pharmaceutical Co., Ltd. and Hubei Wancheng Pharmaceutical Co., Ltd.
2. Is SUPPRELIN LA manufactured exclusively by a single company?
Yes, Tolmar Pharmaceuticals, through its parent Endo Pharmaceuticals, is the sole manufacturer and marketer of SUPPRELIN LA, with no current generic equivalents available.
3. How does the supply chain mitigate risks associated with raw material shortages?
Tolmar diversifies raw material sources and maintains relationships with multiple certified suppliers to prevent disruptions and ensure steady production.
4. What logistical considerations are involved in distributing SUPPRELIN LA?
Distribution requires cold chain logistics, secure storage, and adherence to handling protocols to maintain product stability and integrity during transportation.
5. Could emerging competitors affect SUPPRELIN LA’s supply chain?
Potential development of alternative formulations or bioresorbable implants could introduce new suppliers, altering the current supply landscape and market dynamics.
References
- Food and Drug Administration. SUPPRELIN LA (histrelin acetate implant) Labeling.
- Tolmar Pharmaceuticals. SUPPRELIN LA product information.
- Market analysis reports on bioresorbable polymers and implant manufacturing.
- Global API supplier directories and Good Manufacturing Practice (GMP) certificates.
More… ↓
